Clinical Trials Logo

Filter by:
NCT ID: NCT00849069 Terminated - Clinical trials for Streptococcus Pneumoniae

Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine

Start date: March 12, 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of GSK2231395A candidate vaccine in adults and elderly adults with chronic obstructive pulmonary disease. Subjects will be vaccinated 3 times with an interval of respectively 2 and 10 months.

NCT ID: NCT00848107 Terminated - Systemic Sclerosis Clinical Trials

Open-Label Study of Oral Treprostinil in Digital Ulcers

DISTOL-EXT
Start date: September 2009
Phase: Phase 2
Study type: Interventional

This open label extension trial will allow ongoing treatment of subjects who participated in the randomized controlled trials, and will provide long term information about the safety of treprostinil diethanolamine SR in subjects with SSc and digital ulcers.

NCT ID: NCT00847379 Terminated - Clinical trials for Duchenne Muscular Dystrophy

Phase 2B Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)

Start date: January 31, 2009
Phase: Phase 2
Study type: Interventional

Duchenne/Becker muscular dystrophy (DMD/BMD) is a genetic disorder that develops in boys. It is caused by a mutation in the gene for dystrophin, a protein that is important for maintaining normal muscle structure and function. Loss of dystrophin causes muscle fragility that leads to weakness and loss of walking ability during childhood and teenage years. A specific type of mutation, called a nonsense (premature stop codon) mutation is the cause of DMD/BMD in approximately 10-15% of boys with the disease. Ataluren (PTC124) is an orally delivered, investigational drug that has the potential to overcome the effects of the nonsense mutation. This study is a Phase 2b extension trial that will evaluate the long-term safety of ataluren (PTC124) in boys with nonsense mutation DMD/BMD, as determined by adverse events and laboratory abnormalities. The study will also assess changes in walking, muscle function, and other important clinical and laboratory measures.

NCT ID: NCT00841126 Terminated - Clinical trials for Chronic Kidney Failure

Phase III Study to Investigate the Safety and Efficacy of Fermagate and Lanthanum Carbonate

Start date: July 2009
Phase: Phase 3
Study type: Interventional

Magnesium iron hydroxycarbonate is a phosphate binder that absorbs phosphate from food, reducing the amount that the body can absorb. The purpose of this study is to assess the efficacy of magnesium iron hydroxycarbonate in subjects requiring hemodialysis, compared with a marketed phosphate binder, lanthanum carbonate and placebo.

NCT ID: NCT00836875 Terminated - Clinical trials for Invasive Aspergillosis

A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children

Start date: May 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety profile of voriconazole (an antifungal drug) when used in children who have invasive aspergillosis (IA) and other rare systemic fungal infections.

NCT ID: NCT00833300 Terminated - Delirium Clinical Trials

Haloperidol vs Olanzapine for the Management of ICU Delirium

Start date: June 2008
Phase: N/A
Study type: Interventional

The purpose of this randomized clinical trial is to determine whether haloperidol is superior to olanzapine for the treatment of ICU acquired delirium. The hypothesis is that haloperidol is in fact superior to olanzapine in treating ICU acquired delirium and sustaining delirium free time.

NCT ID: NCT00832507 Terminated - Clinical trials for Pulmonary Arterial Hypertension

Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)

Start date: January 2009
Phase: Phase 2
Study type: Interventional

This Phase 2, randomized, double-blind, placebo-controlled, multicenter, dose-ranging study will compare the efficacy, safety, and tolerability of cicletanine hydrochloride (HCl) to placebo in subjects with PAH. Study drug will be administered alone, or on the background of stable PAH therapy. The study will consist of 3 periods: a screening period, a 12-week placebo-controlled treatment period, and a long-term, blinded extension period.

NCT ID: NCT00831441 Terminated - Clinical trials for Acute Coronary Syndrome

Phase III Acute Coronary Syndrome

APPRAISE-2
Start date: March 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if apixaban is superior to placebo for preventing cardiovascular death, non-fatal myocardial infarction, or ischemic stroke in subjects with a recent acute coronary syndrome

NCT ID: NCT00827658 Terminated - Hand Surgery Clinical Trials

Ulnar Nerve Block for Procedural Anesthesia - Wrist Versus Palm

Start date: February 2008
Phase: N/A
Study type: Interventional

Ulnar nerve blockade is necessary for sensory anesthesia and analgesia in the hand during minor procedures. The course of the ulnar nerve in the forearm, wrist, and hand is predictable and has low variability. However even with known anatomic location and landmarks, ulnar nerve blocks at the wrist frequently are inadequate for procedural anesthesia. The antebrachial fascia at the wrist acts as a barrier to local infiltration. Since the fascia can not be visualized or palpated, it is commonly not penetrated, resulting in an inadequate block. Furthermore at the level of the wrist the ulnar artery lies in close proximity to the nerve and there is potential for arterial puncture while attempting injection for volar wrist block. The palmar ulnar nerve block is an injection distal to the hook of the hamate in the thenar eminence which avoids the ulnar artery and antebrachial fascia. This block has been used successfully for many years in clinical practice but has not been assessed or compared in a research study. The purpose of this study is to assess the validity of using a palmar ulnar nerve block for procedures in the hand as compared to the standard volar wrist ulnar nerve block.

NCT ID: NCT00819754 Terminated - Clinical trials for Metastatic Colorectal Cancer

A Phase I/II Study of IXO With Bevacizumab in Patients With Metastatic Colorectal Cancer

IXO+A
Start date: November 2003
Phase: Phase 1/Phase 2
Study type: Interventional

Triplets of irinotecan, oxaliplatin and infusional 5-fluorouracil(FU)/leucovorin (LV) are associated with high response rates and long survival as first-line treatment for metastatic colorectal cancer (mCRC). The oral fluoropyrimidine, capecitabine, is better tolerated and shows better response rates than 5-FU/LV in metastatic colorectal cancer. A phase I dose-escalation study established dose limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended phase II doses (RPIID) of irinotecan, oxaliplatin and capecitabine. This phase I /II study is to determine dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), phase II recommended dose (RD) of IXO and bevacizumab combination and safety at the RD in an expanded cohort.